Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

ARRA boosts cancer programs but impact on personalized medicine unclear

Nature Biotechnology volume 27, page 1062 (2009)Cite this article

Access through your institution
Buy or subscribe

The cancer field is poised to thrive under ARRA, but support for diagnostic firms that could further the goal of personalizing cancer therapeutics has been less forthcoming. According to the Office of the Director, the National Cancer Institute received $1.26 billion of the NIH's ARRA monies, including $731 million in grants, $494 million in R&D contracts for the academic community, $6 million for intramural funding and $25 million of support. Eighteen of the 37 challenge grants NCI sent to NIH are being funded to the tune of $17.7 million; plus NIH is putting up $38 million to cover 41 additional high-priority NCI grants. There's also $36 million going to fund 37 early-phase clinical trials of compounds that, according to NCI director John Niederhuber, “we hope will soon expand our ability to provide targeted, personalized medicine.”

Nonetheless, according to some observers, ARRA's impact on personalized medicine and cancer treatment, where the bulk of such research is focused, could be greater.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Mark Ratner
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ratner, M. ARRA boosts cancer programs but impact on personalized medicine unclear. Nat Biotechnol 27, 1062 (2009). https://doi.org/10.1038/nbt1209-1062

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt1209-1062

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing